Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction.

"Conflicts of interest. MPP is an investigator for Trevi Therapeutics; a consultant for Galderma; and has received speaker honoraria/travel fees from Galderma, Menlo Therapeutics, Novartis and Trevi Therapeutics. CZ has received speaker honoraria/travel fees from Beiersdorf and Dermasence. EW is an investigator for Menlo Therapeutics, Trevi Therapeutics, Kiniksa Pharmaceuticals and a member of the advisory board meetings for Menlo and Trevi. SG has received consulting support from companies, including Menlo Therapeutics. LM is a consultant for Galderma, Menlo, Trevi, Sanofi, and was investigator for Galderma, Trevi, Sanofi. EB is an investigator for Biogen, Galderma, and is a consultant and/or member of the advisory board for Janssen, Lilly, Celgene, Novartis, Pfizer, and received financial support from Sanofi, Abbvie. AL is a consultant for Galderma and Novartis; and has received speaker honoraria/travel fees from Galderma, Bayer, LEO, Pierre Fabre. SB has received speaker honoraria/travel fees from LEO. JCS is an investigator for AbbVie, Amgen, Janssen, Menlo Therapeutics, Merck, Novartis, Regeneron, Trevi, UCB, Galapagos, Pfizer, Helm, InflaRX, Incyte; advisor for AbbVie, Leo Pharma, Novartis, Pierre-Fabre, Menlo Therapeutics, Trevi and speaker for AbbVie, Novartis, Sanofi-Genzyme, Janssen, Leo Pharma, Novartis, SunFarm, Eli Lilly. AR is a consultant or speaker for AbbVie, Bioderma, Celgene, Chema Elektromet, Eli Lilly, Galderma, Janssen, Leo Pharma, Medac, Menlo Therapeutics, Novartis, Pierre-Fabre, Sandoz and Trevi; Principal Investigator or Subinvestigator in clinical trials sponsored by AbbVie, Drug Delivery Solutions Ltd, Galderma, Genentech, Janssen, Kymab Limited, Leo Pharma, Menlo Therapeutics, MetrioPharm, MSD, Novartis, Pfizer and Trevi. FJL is an investigator for DS Biopharma, Eli Lilly, Galderma, Pfizer, Menlo Therapeutics, Trevi Therapeutics. He is a member of the advisory boards and/or has received speaker honoraria/travel fees from AbbVie, Almirall, Celgene, Eli Lilly, Janssen, Leo Pharma, Menlo Therapeutics, Novartis, Pfizer, Trevi Therapeutics. MM has received honoraria as a speaker and/or consultant for Amgen, Aralez, argenx, Bayer, Beiersdorf, Celgene, Galderma, Menlo, Moxie, Novartis, Roche, Sanofi, Shire, Uriach. MS is a consultant and member of advisory boards of AbbVie, Almirall, Celgene, Eli Lilly, Janssen-Cilag, Menlo, Novartis and Pfizer. He has received speaker honoraria/travel fees from AbbVie and Novartis. ES-B is an investigator, a consultant or gave presentations for Regeneron, Sanofi, Stiefel/GSK, Pierre Fabre, La Roche Posay, Leo Pharma, Novartis, Almirall, Pfizer, Galderma, Lilly, Abbvie. MG has been a consultant and received speaker honoraria for Novartis and Sanofi. MA reports receiving speakers honoraria or grants from, or participated in clinical trials or health services research projects for Abbott/AbbVie, Almirall, Amgen, Biogen Idec, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, Forward Pharma, Galderma, GSK, Hexal, Janssen, LEO Pharma, Medac, MSD, Novartis, Pfizer, Sandoz, Teva, TK, Trevi, and Xenoport. MD is co-founder of Hippokrates IT. SS is an investigator for Dermasence, Galderma, Kiniksa Pharmaceuticals, Menlo Therapeutics, Trevi Therapeutics, Novartis, Sanofi, and Vanda Pharmaceuticals Inc.; and is a consultant and/or member of the advisory board for Almirall, Bayer, Beiersdorf, Bellus Health, Bionorica, Cara Therapeutics, Celgene, Clexio Biosciences, DS Biopharma, Galderma, Menlo Therapeutics, Novartis, Perrigo, and Trevi Therapeutics. TAL has been a consultant for Menlo and Novartis. HFS is an advisor and/or investigator for Menlo Therapeutics, Abbvie and Novartis. JW, JAH, ES, NNP, AB, MS, TN, VH, SaS, IG, FD, JE, CF, UG, CR and GS have no conflicts of interest."

"This study was supported by the European Academy of Dermatology and Venereology (EADV, No. 2016-012 to MP). Galderma S.A, Kiniksa Pharmaceuticals and Menlo Therapeutics provided support for the study."

"In this study, 15 European centres from 5 regions, i.e. Germany (Münster, Berlin, Heidelberg), Northern Europe (Norway – Oslo, Sweden – Lund), Central Europe (Austria – Graz, France – Brest, Switzerland – Aarau), Eastern Europe (Poland – Rzeszow, Poland – Wroclaw, Russia – Moscow), and Southern Europe (Italy – Rome, Portugal – Coimbra, Spain – Barcelona, Turkey – Aydin) participated. The ethics committees corresponding to the participating centres approved the study (main ethics committee: Medical Faculty of the University of Münster, 2017-168-f-S), which was performed according to the Declaration of Helsinki. The study is registered at the German registry of clinical trials (DRKS00012876, registration date: 09.08.2017)."